245 related articles for article (PubMed ID: 35421925)
21. Role and potential clinical utility of ARID1A in gastrointestinal malignancy.
Wang R; Chen M; Ye X; Poon K
Mutat Res Rev Mutat Res; 2021; 787():108360. PubMed ID: 34083049
[TBL] [Abstract][Full Text] [Related]
22. Potential therapeutic targets in ARID1A-mutated cancers.
Bitler BG; Fatkhutdinov N; Zhang R
Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
[TBL] [Abstract][Full Text] [Related]
23. ARID1A loss in cancer: Towards a mechanistic understanding.
Mathur R
Pharmacol Ther; 2018 Oct; 190():15-23. PubMed ID: 29730444
[TBL] [Abstract][Full Text] [Related]
24. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
25. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.
Kamori T; Oki E; Shimada Y; Hu Q; Hisamatsu Y; Ando K; Shimokawa M; Wakai T; Oda Y; Mori M
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1420. PubMed ID: 34042312
[TBL] [Abstract][Full Text] [Related]
26. [Tumor suppressor role of chromatin-remodeling factor ARID1A].
Guo XQ; Zhang QX; Huang WR; Duan XL; Cai ZM
Yi Chuan; 2013 Mar; 35(3):255-61. PubMed ID: 23575531
[TBL] [Abstract][Full Text] [Related]
27. Switch/sucrose nonfermenting nucleosome complex-deficient colorectal carcinomas have distinct clinicopathologic features.
Villatoro TM; Ma C; Pai RK
Hum Pathol; 2020 May; 99():53-61. PubMed ID: 32222462
[TBL] [Abstract][Full Text] [Related]
28. Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer.
Cajuso T; Hänninen UA; Kondelin J; Gylfe AE; Tanskanen T; Katainen R; Pitkänen E; Ristolainen H; Kaasinen E; Taipale M; Taipale J; Böhm J; Renkonen-Sinisalo L; Mecklin JP; Järvinen H; Tuupanen S; Kilpivaara O; Vahteristo P
Int J Cancer; 2014 Aug; 135(3):611-23. PubMed ID: 24382590
[TBL] [Abstract][Full Text] [Related]
29. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
30. The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.
Kartha N; Shen L; Maskin C; Wallace M; Schimenti JC
Genetics; 2016 Aug; 203(4):1601-11. PubMed ID: 27280691
[TBL] [Abstract][Full Text] [Related]
31. ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Helming KC; Wang X; Wilson BG; Vazquez F; Haswell JR; Manchester HE; Kim Y; Kryukov GV; Ghandi M; Aguirre AJ; Jagani Z; Wang Z; Garraway LA; Hahn WC; Roberts CW
Nat Med; 2014 Mar; 20(3):251-4. PubMed ID: 24562383
[TBL] [Abstract][Full Text] [Related]
32. The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma.
Lichner Z; Scorilas A; White NM; Girgis AH; Rotstein L; Wiegand KC; Latif A; Chow C; Huntsman D; Yousef GM
Am J Pathol; 2013 Apr; 182(4):1163-70. PubMed ID: 23416164
[TBL] [Abstract][Full Text] [Related]
33. DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter.
Shao K; Pu W; Zhang J; Guo S; Qian F; Glurich I; Jin Q; Ma Y; Ju S; Zhang Z; Ding W
Clin Epigenetics; 2021 Apr; 13(1):89. PubMed ID: 33892791
[TBL] [Abstract][Full Text] [Related]
34. Unique characteristics of
Kim YS; Jeong H; Choi JW; Oh HE; Lee JH
Saudi J Gastroenterol; 2017; 23(5):268-274. PubMed ID: 28937020
[TBL] [Abstract][Full Text] [Related]
35. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
36. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.
Wang DD; Chen YB; Pan K; Wang W; Chen SP; Chen JG; Zhao JJ; Lv L; Pan QZ; Li YQ; Wang QJ; Huang LX; Ke ML; He J; Xia JC
PLoS One; 2012; 7(7):e40364. PubMed ID: 22808142
[TBL] [Abstract][Full Text] [Related]
37. ARID1A deficient undifferentiated spindle cell and rhabdoid sarcoma of the prostate: report of a unique case with emphasis on diagnostic implications.
Xu W; Dong H; Ru G; Zhao M
Diagn Pathol; 2022 Feb; 17(1):22. PubMed ID: 35125107
[TBL] [Abstract][Full Text] [Related]
38. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
Guan B; Wang TL; Shih IeM
Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
[TBL] [Abstract][Full Text] [Related]
39. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
Lee SK; Hwang JH; Choi KY
Adv Biol Regul; 2018 May; 68():46-54. PubMed ID: 29449169
[TBL] [Abstract][Full Text] [Related]
40. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.
Reske JJ; Wilson MR; Holladay J; Siwicki RA; Skalski H; Harkins S; Adams M; Risinger JI; Hostetter G; Lin K; Chandler RL
PLoS Genet; 2021 Dec; 17(12):e1009986. PubMed ID: 34941867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
